Scribe Therapeutics is a biotechnology company that develops CRISPR-based genetic medicines. The company's platform leverages the CRISPR-Cas technology to develop therapies for genetic diseases. Scribe Therapeutics was founded in 2018 by Jennifer Doudna, Benjamin Oakes, Brett Staahl, and Jonathan Weissman. The company is headquartered in South San Francisco, California.